Minocycline in Patients With Huntington's Disease

Official Title: “Minocycline Dosing and Safety in Huntington's Disease”

This is a study to determine whether treatment with minocycline is safe and tolerable in patients with Huntington's disease (HD) and whether minocycline reduces symptoms of HD in these patients.

Huntington's disease (HD) is a dominantly inherited disorder. It is uniformly progressive and there is no known effective treatment or cure. The pathogenesis is largely unknown; however, recent studies implicate caspase activation, glutamate excitotoxicity, and free radical toxicity as possible causes of HD. Pharmacological agents that block these pathways may be therapeutic in HD. Minocycline is an antibiotic that also inhibits caspase-1 and caspase-3 expression, and inducible nitric oxide synthetase activity, which are factors that may play an important role in the mechanisms of neuropathology in HD.

Two dosages of minocycline or placebo will be given to ambulatory patients with HD over an 8-week period and the tolerability will be compared. Additional measures of safety and the change in motor, behavior, cognitive, and function features will be examined.

Intervention(s) in this Clinical Trial

• Drug: Minocycline

Inclusion criteria:

• Clinical features of Huntington's disease (HD) and a confirmatory family history of HD and/or a CAG repeat expansion of at least 37
• Stage I, II, or III of illness (TFC greater than or equal to 5)
• Ambulatory and not requiring skilled nursing care
• Patients must use effective birth control
• Concurrent psychotropic medications must be at stable dose for at least 4 weeks prior to study
• WBC count at least 3,800/mm3
• Creatinine no greater than 2.0
• Alanine aminotransferase (ALT) no greater than 2 times upper limit of normal

Exclusion criteria:

• Prior minocycline use within 2 months of baseline visit
• History of known sensitivity or intolerability to minocycline or any other tetracycline
• History of vestibular disease
• Use of any investigational drug within 30 days of baseline visit
• Treatment with any drug that may cause lupus-like symptoms (e.g., procainamide or hydralazine) within 4 weeks of baseline visit
• Pregnant or nursing
• Underlying hematologic, hepatic, or renal disease
• Evidence of unstable medical illness
• Illness that requires use of coumadin
• Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression within 90 days of baseline visit, or suicidal ideation
• Substance (alcohol or drug) abuse within 1 year of baseline visit
• History of systemic lupus erythematosis (SLE) or a history of SLE in a first-degree relative
• Positive ANA screening (at or above 1:80)

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: FDA Office of Orphan Products Development U.S. Fed

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00029874

Study ID Number: FD-R-1968-01

ClinicalTrials.gov Identifier: NCT00029874

Health Authority: United States: Food and Drug Administration